Schonfeld Strategic Advisors’s PharmaCyte Biotech PMCB Stock Holding History
Bought
Maintained
Sold
Other funds holding PMCB
XT
EPM
Schonfeld Strategic Advisors's PMCB Position: Q2 2026 in Review
Schonfeld Strategic Advisors reduced its PharmaCyte Biotech (PMCB) stake by 0.31% in Q2 2026, selling an estimated $62 and leaving 26,926 shares worth $20.7K. The position accounts for ﹤0.01% of the portfolio, ranked #2451.
Schonfeld Strategic Advisors first reported a position in PMCB in Q3 2021 and has held it in 20 quarters since. The position peaked at $280K in Q3 2021. 28 funds tracked by Wall St. Rank hold PMCB as of Q2 2026.
- Schonfeld Strategic Advisors held 26,926 shares of PharmaCyte Biotech worth $20.7K as of Q2 2026.
- Schonfeld Strategic Advisors sold 83 PharmaCyte Biotech shares in Q2 2026, an estimated $62.
- PharmaCyte Biotech made up ﹤0.01% of Schonfeld Strategic Advisors's portfolio in Q2 2026, its #2451 holding.
- Schonfeld Strategic Advisors first reported a position in PharmaCyte Biotech in Q3 2021 and has held it in 20 quarters since.
- Schonfeld Strategic Advisors's PharmaCyte Biotech position peaked at $280K in Q3 2021.
- 28 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q2 2026.
Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.